## FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Washington, D.C. 20549

ECUR	11169	AND	EXCI	TANGE	COMIMI	<b>3310</b>
١.	۸ / ــ ــ امـ : مـ ا	- 000	0540			

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to exist the office of the indicate of the restrict of the office of the section. to satisfy the affirmative defense conditions of Rule 10b5-1(c). See

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     CONTE LISA A					2. Issuer Name <b>and</b> Ticker or Trading Symbol  Jaguar Health, Inc. [ JAGX ]							(Che	Relationship of Reporting Person(s) to Issuer (Check all applicable)							
CONTELISA A															Directo			10% Ow	·	
(Last) (First) (Middle)					-										<ul><li>Officer below)</li></ul>	Officer (give title below)			pecify	
(Last) (First) (Middle) C/O JAGUAR HEALTH, INC.						3. Date of Earliest Transaction (Month/Day/Year) 10/08/2024									below) below) See Remarks					
<b>'</b>				'	10/00/2021															
200 PINE STREET, SUITE 400					L															
(Street)					4.	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
SAN		٨	0.410.4									/ / Form fi								
FRANCI	FRANCISCO CA 94104		94104												Form filed by More than One Reporting					
															Person	-				
(City)	(S	tate)	(Zip)																	
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)						Execution Da		n Date,	Code (Inst		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4		ed (A) or tr. 3, 4 and	5. Amour Securitie Beneficia Owned F	s Form ally (D) of ollowing (I) (I		: Direct     r Indirect     str. 4)   (	7. Nature of Indirect Beneficial Ownership		
									Cod	v	Amoun	Amount (A) or (D)		Price	Reported Transact (Instr. 3 a	Reported Transaction(s) (Instr. 3 and 4)			Instr. 4)	
Common Stock <sup>(1)</sup> 10/0			10/08/2	2024 <sup>(2)(3)</sup>			A		16,5	16,503 A		\$0	16,624(4)			D				
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
				(e.g., p	outs	, call	s, warr	ants	, optic	ns,	convert	ible	secu	rities)						
Derivative Conversion Date		3. Transaction Date (Month/Day/Year)	e Execution D		Date, Transaction Code (Ins				6. Date Exercisable and Expiration Date (Month/Day/Year)		of S Und Deri	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
											Amount or		(Instr. 4)							
			Co	ode	v	(A)		Date Exercisa		Expiration Date										
Stock option (right to buy) <sup>(1)</sup>	\$1.29	10/08/2024 <sup>(2)</sup>			A		132,020		(5)		10/08/2034		nmon ock	132,020	\$0	132,02	20	D		

## Explanation of Responses:

- 1. Granted pursuant to the issuer's 2014 Stock Incentive Plan.
- 2. The option and restricted stock unit grants were approved by the issuer's board of directors on October 8, 2024.
- 3. Each restricted stock unit represents a contingent right to receive one share of the issuer's voting common stock. The restricted stock units vest in three equal annual installments beginning on October 8, 2025. Vested shares will be delivered to the reporting person on the vesting date or dates provided in the grant notice.
- 4. On May 23, 2024, the issuer effected a 60-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "Reverse Stock Split). Upon effectiveness of the Reverse Stock Split, every 60 shares of voting common stock was automatically converted into one share of voting common stock.
- 5. The options will vest ratably on a monthly basis over 36 months from the grant date, so long as the executive remains employed by the issuer.

## Remarks:

Chief Executive Officer and President

/s/ Lisa A. Conte, Lisa A. Conte 10/10/2024

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.